A potent anti-malarial human monoclonal antibody targets circumsporozoite protein minor repeats and neutralizes sporozoites in the liver

LT Wang, LS Pereira, Y Flores-Garcia, J O'Connor… - Immunity, 2020 - cell.com
Discovering potent human monoclonal antibodies (mAbs) targeting the Plasmodium
falciparum circumsporozoite protein (PfCSP) on sporozoites (SPZ) and elucidating their …

Roles of virtual screening and molecular dynamics simulations in discovering and understanding antimalarial drugs

SS Duay, RCY Yap, AL Gaitano III, JAA Santos… - International Journal of …, 2023 - mdpi.com
Malaria continues to be a global health threat, with approximately 247 million cases
worldwide. Despite therapeutic interventions being available, patient compliance is a …

Application of liposomes in the treatment of infectious diseases

NAA Suhaimi, S Ahmad, SMN Husna, ME Sarmiento… - Life Sciences, 2022 - Elsevier
The advances in the development of drugs and vaccines for major infectious diseases of
tuberculosis (TB), malaria and HIV represent some of the most significant milestones in their …

A novel CSP C-terminal epitope targeted by an antibody with protective activity against Plasmodium falciparum

N Beutler, T Pholcharee, D Oyen… - PLoS …, 2022 - journals.plos.org
Potent and durable vaccine responses will be required for control of malaria caused by
Plasmodium falciparum (Pf). RTS, S/AS01 is the first, and to date, the only vaccine that has …

An epitope-based malaria vaccine targeting the junctional region of circumsporozoite protein

L Jelínková, H Jhun, A Eaton, N Petrovsky, F Zavala… - npj Vaccines, 2021 - nature.com
A malaria vaccine that elicits long-lasting protection and is suitable for use in endemic areas
remains urgently needed. Here, we assessed the immunogenicity and prophylactic efficacy …

In vitro and in vivo inhibition of malaria parasite infection by monoclonal antibodies against Plasmodium falciparum circumsporozoite protein (CSP)

MC Livingstone, AA Bitzer, A Giri, K Luo… - Scientific reports, 2021 - nature.com
Plasmodium falciparum malaria contributes to a significant global disease burden.
Circumsporozoite protein (CSP), the most abundant sporozoite stage antigen, is a prime …

Structural and biophysical correlation of anti-NANP antibodies with in vivo protection against P. falciparum

T Pholcharee, D Oyen, Y Flores-Garcia… - Nature …, 2021 - nature.com
The most advanced P. falciparum circumsporozoite protein-based malaria vaccine, RTS,
S/AS01 (RTS, S), confers partial protection but with antibody titers that wane relatively …

Vaccination in a humanized mouse model elicits highly protective PfCSP-targeting anti-malarial antibodies

S Kratochvil, CH Shen, YC Lin, K Xu, U Nair… - Immunity, 2021 - cell.com
Repeat antigens, such as the Plasmodium falciparum circumsporozoite protein (PfCSP), use
both sequence degeneracy and structural diversity to evade the immune response. A few …

Restricted valency (NPNA)n repeats and junctional epitope-based circumsporozoite protein vaccines against Plasmodium falciparum

MD Langowski, FA Khan, S Savransky, DR Brown… - npj Vaccines, 2022 - nature.com
Abstract The Circumsporozoite Protein (CSP) of Plasmodium falciparum contains an N-
terminal region, a conserved Region I (RI), a junctional region, 25–42 copies of major …

[HTML][HTML] Molecular determinants of cross-reactivity and potency by VH3-33 antibodies against the Plasmodium falciparum circumsporozoite protein

E Thai, R Murugan, Š Binter, CB Aschner, K Prieto… - Cell Reports, 2023 - cell.com
Summary IGHV3-33-encoded antibodies are prevalent in the human humoral response
against the Plasmodium falciparum circumsporozoite protein (PfCSP). Among VH3-33 …